Renal Cancer - Results from #620

Silencing of genes by promoter hypermethylation shapes tumor microenvironment and resistance to immunotherapy in clear-cell renal cell carcinomas. November 17, 2023

An Observational Case-Control Study on Parental Age and Childhood Renal Tumors. November 16, 2023

Diagnostic Value Analysis of Multi-Slice Helical Computed Tomography Reconstruction Parameters Combined with 3.0 T Magnetic Resonance in Clear Cell Renal Cell Carcinoma. November 16, 2023

Single-Probe Percutaneous Cryoablation with Liquid Nitrogen for the Treatment of T1a Renal Tumors. November 15, 2023

Impact of Immunotherapy on Real-World Survival Outcomes in Metastatic Renal Cell Carcinoma. November 15, 2023

Could a Risk-adapted Approach Support Shared Decision-making Regarding Eligibility for Adjuvant Pembrolizumab for Patients with Clear Cell Renal Cell Carcinoma at High Risk of Recurrence? A Multicentre Cohort Study. November 14, 2023

Immune approaches beyond traditional immune checkpoint inhibitors for advanced renal cell carcinoma. November 14, 2023

A Phase 2 Trial of Talazoparib and Avelumab in Genomically Defined Metastatic Kidney Cancer. November 13, 2023

A Pooled Analysis of 3 Phase II Trials of Salvage Nivolumab/Ipilimumab After Nivolumab in Renal Cell Carcinoma. November 13, 2023

Exelixis Announces Encouraging Results from Expansion Cohort of Phase 1b STELLAR-001 Trial Evaluating Zanzalintinib in Patients with Advanced Kidney Cancer at IKCS 2023 November 10, 2023

Prognostic Stratification by the Meet-URO Score in Real-World Older Patients With Metastatic Renal Cell Carcinoma (mRCC) Receiving Cabozantinib: A Subanalysis of the Prospective ZEBRA Study (Meet-URO 9). November 9, 2023

Prognosis, Immune Microenvironment Infiltration and Immunotherapy Response in Clear Cell Renal Cell Carcinoma Based on Cuproptosis-related Immune Checkpoint Gene Signature. November 9, 2023

Real-World Results of Cabozantinib Given as Alternative Schedule in Metastatic Renal Cell Carcinoma. November 9, 2023

Multicystic Clear Cell Renal Tumors With Low-grade Nuclear Features: Time to Include TFE3 Translocation-associated Carcinomas. November 9, 2023

Predictors of disease recurrence in high-risk non-metastatic renal cell carcinoma patient's post-surgical resection: A single-center, retrospective study. November 8, 2023

Standard Versus Modified Ipilimumab, in Combination With Nivolumab, in Advanced Renal Cell Carcinoma: A Randomized Phase II Trial (PRISM). November 8, 2023

Inflammatory response-based prognostication and personalized therapy decisions in clear cell renal cell cancer to aid precision oncology. November 7, 2023

Renal Cell Cancer - Insights in Drug Resistance Mechanisms. November 7, 2023

Surgical Management and Oncologic Outcomes of Renal Cell Carcinoma and Inferior Vena Caval Thrombi with Aggressive Histologic Variants. November 7, 2023

Clinical Application of Digital and Computational Pathology in Renal Cell Carcinoma: A Systematic Review. November 6, 2023

Page 32 of 455